Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Breast Cancer

  Free Subscription


20.03.2017

4 BMC Cancer
2 Br J Cancer
4 Breast Cancer (Dove Med Press)
3 Breast Cancer Res
7 Breast Cancer Res Treat
4 Breast J
3 Cancer
1 Cancer Chemother Pharmacol
1 Cancer Epidemiol Biomarkers Prev
2 Cancer Lett
1 Cancer Res
2 Clin Breast Cancer
2 Clin Cancer Res
2 Eur J Cancer
1 Eur J Surg Oncol
1 Eur Radiol
1 Gene
1 Int J Cancer
1 J Clin Oncol
1 J Nucl Med
1 J Pathol
1 JAMA
1 Oncogene
4 Oncol Rep
1 PLoS Comput Biol
9 PLoS One


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    BMC Cancer

  1. LIM JP, Shyamasundar S, Gunaratne J, Scully OJ, et al
    YBX1 gene silencing inhibits migratory and invasive potential via CORO1C in breast cancer in vitro.
    BMC Cancer. 2017;17:201.
    PubMed     Text format     Abstract available

  2. DODOVA RI, Mitkova AV, Dacheva DR, Hadjo LB, et al
    Erratum to: Spectrum and frequencies of BRCA1/2 mutations in Bulgarian high risk breast cancer patients.
    BMC Cancer. 2017;17:195.
    PubMed     Text format    

  3. HUANG Y, Burns DJ, Rich BE, MacNeil IA, et al
    Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.
    BMC Cancer. 2017;17:199.
    PubMed     Text format     Abstract available

  4. DOS SANTOS AF, Terra LF, Wailemann RA, Oliveira TC, et al
    Methylene blue photodynamic therapy induces selective and massive cell death in human breast cancer cells.
    BMC Cancer. 2017;17:194.
    PubMed     Text format     Abstract available


    Br J Cancer

  5. ALTUNDAG K
    Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy'.
    Br J Cancer. 2017 Mar 14. doi: 10.1038/bjc.2017.
    PubMed     Text format    

  6. FUJII T, Ueno NT
    Reply to 'Comment on 'Nomogram to predict pathologic complete response in HER2-positive breast cancer treated with neoadjuvant systemic therapy''.
    Br J Cancer. 2017 Mar 14. doi: 10.1038/bjc.2017.
    PubMed     Text format    


    Breast Cancer (Dove Med Press)

  7. BUWENGE M, Cammelli S, Ammendolia I, Tolento G, et al
    Intensity modulated radiation therapy for breast cancer: current perspectives.
    Breast Cancer (Dove Med Press). 2017;9:121-126.
    PubMed     Text format     Abstract available

  8. TALEBI BEZMIN ABADI A
    Comment on "Gastric and colon metastasis from breast cancer: case report, review of the literature, and possible underlying mechanisms".
    Breast Cancer (Dove Med Press). 2017;9:59-60.
    PubMed     Text format    

  9. DING Z, Joy M, Kameneva MV, Roy P, et al
    Nanomolar concentration of blood-soluble drag-reducing polymer inhibits experimental metastasis of human breast cancer cells.
    Breast Cancer (Dove Med Press). 2017;9:61-65.
    PubMed     Text format     Abstract available

  10. SAMBI M, Haq S, Samuel V, Qorri B, et al
    Alternative therapies for metastatic breast cancer: multimodal approach targeting tumor cell heterogeneity.
    Breast Cancer (Dove Med Press). 2017;9:85-93.
    PubMed     Text format     Abstract available


    Breast Cancer Res

  11. LI M, Tse LA, Chan WC, Kwok CH, et al
    Nighttime eating and breast cancer among Chinese women in Hong Kong.
    Breast Cancer Res. 2017;19:31.
    PubMed     Text format     Abstract available

  12. ERIKSSON M, Czene K, Pawitan Y, Leifland K, et al
    A clinical model for identifying the short-term risk of breast cancer.
    Breast Cancer Res. 2017;19:29.
    PubMed     Text format     Abstract available

  13. WALKER LC, Pearson JF, Wiggins GA, Giles GG, et al
    Increased genomic burden of germline copy number variants is associated with early onset breast cancer: Australian breast cancer family registry.
    Breast Cancer Res. 2017;19:30.
    PubMed     Text format     Abstract available


    Breast Cancer Res Treat

  14. ZHANG S, Gao X, Fu W, Li S, et al
    Immunoglobulin-like domain 4-mediated ligand-independent dimerization triggers VEGFR-2 activation in HUVECs and VEGFR2-positive breast cancer cells.
    Breast Cancer Res Treat. 2017 Mar 16. doi: 10.1007/s10549-017-4189.
    PubMed     Text format     Abstract available

  15. TSENG LM, Chiu JH, Liu CY, Tsai YF, et al
    A comparison of the molecular subtypes of triple-negative breast cancer among non-Asian and Taiwanese women.
    Breast Cancer Res Treat. 2017 Mar 15. doi: 10.1007/s10549-017-4195.
    PubMed     Text format     Abstract available

  16. KIMMICK GG, Major B, Clapp J, Sloan J, et al
    Using ePrognosis to estimate 2-year all-cause mortality in older women with breast cancer: Cancer and Leukemia Group B (CALGB) 49907 and 369901 (Alliance A151503).
    Breast Cancer Res Treat. 2017 Mar 10. doi: 10.1007/s10549-017-4188.
    PubMed     Text format     Abstract available

  17. GERSHUNI V, Li YR, Williams AD, So A, et al
    Breast cancer subtype distribution is different in normal weight, overweight, and obese women.
    Breast Cancer Res Treat. 2017 Mar 14. doi: 10.1007/s10549-017-4192.
    PubMed     Text format     Abstract available

  18. KJARTANSDOTTIR OJ, Sigurdardottir LG, Olafsdottir EJ, Jonasson JG, et al
    Estrogen-progestin use and breast cancer characteristics in lean and overweight postmenopausal women.
    Breast Cancer Res Treat. 2017 Mar 9. doi: 10.1007/s10549-017-4171.
    PubMed     Text format     Abstract available

  19. YANAGAWA T, Kagara N, Miyake T, Tanei T, et al
    Detection of ESR1 mutations in plasma and tumors from metastatic breast cancer patients using next-generation sequencing.
    Breast Cancer Res Treat. 2017 Mar 10. doi: 10.1007/s10549-017-4190.
    PubMed     Text format     Abstract available

  20. DIECI MV, Frassoldati A, Generali D, Bisagni G, et al
    Tumor-infiltrating lymphocytes and molecular response after neoadjuvant therapy for HR+/HER2- breast cancer: results from two prospective trials.
    Breast Cancer Res Treat. 2017 Mar 13. doi: 10.1007/s10549-017-4191.
    PubMed     Text format     Abstract available


    Breast J

  21. GRIMM LJ, Zhang J, Baker JA, Soo MS, et al
    Relationships Between MRI Breast Imaging-Reporting and Data System (BI-RADS) Lexicon Descriptors and Breast Cancer Molecular Subtypes: Internal Enhancement is Associated with Luminal B Subtype.
    Breast J. 2017 Mar 13. doi: 10.1111/tbj.12799.
    PubMed     Text format     Abstract available

  22. GUTH AA, Chun Kim J, Schwartz S, Montes J, et al
    The Relationship of Race, Oncotype DX, and Ki67 in a Population Highly Screened For Breast Cancer.
    Breast J. 2017;23:177-181.
    PubMed     Text format     Abstract available

  23. GROBMYER SR, Abraham J
    Putting Breast Cancer Patients First.
    Breast J. 2017;23:125-126.
    PubMed     Text format    

  24. KANTOR O, Pesce C, Liederbach E, Wang CH, et al
    Are the ACOSOG Z0011 Trial Findings Being Applied to Breast Cancer Patients Undergoing Neoadjuvant Chemotherapy?
    Breast J. 2017 Mar 13. doi: 10.1111/tbj.12793.
    PubMed     Text format     Abstract available


    Cancer

  25. HENRY NL, Braun TM, Breslin TM, Gorski DH, et al
    Variation in the use of advanced imaging at the time of breast cancer diagnosis in a statewide registry.
    Cancer. 2017 Mar 16. doi: 10.1002/cncr.30674.
    PubMed     Text format     Abstract available

  26. CESPEDES FELICIANO EM, Kwan ML, Kushi LH, Chen WY, et al
    Body mass index, PAM50 subtype, recurrence and survival among patients with nonmetastatic breast cancer.
    Cancer. 2017 Mar 13. doi: 10.1002/cncr.30637.
    PubMed     Text format     Abstract available

  27. LIN HY, Bedrosian I, Babiera GV, Shaitelman SF, et al
    Using the National Cancer Data Base for quality evaluation to assess adherence to treatment guidelines for nonmetastatic inflammatory breast cancer.
    Cancer. 2017 Mar 13. doi: 10.1002/cncr.30660.
    PubMed     Text format     Abstract available


    Cancer Chemother Pharmacol

  28. TANDIA M, Mhiri A, Paule B, Saffroy R, et al
    Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
    Cancer Chemother Pharmacol. 2017 Mar 13. doi: 10.1007/s00280-017-3268.
    PubMed     Text format     Abstract available


    Cancer Epidemiol Biomarkers Prev

  29. NELSON SH, Brasky TM, Patterson RE, Laughlin GA, et al
    The association of the C-reactive protein inflammatory biomarker with breast cancer incidence and mortality in the Women's Health Initiative.
    Cancer Epidemiol Biomarkers Prev. 2017 Mar 14. pii: cebp.1005.2016.
    PubMed     Text format     Abstract available


    Cancer Lett

  30. MONTEIRO FL, Vitorino R, Wang J, Cardoso H, et al
    The histone H2A isoform Hist2h2ac is a novel regulator of proliferation and epithelial-mesenchymal transition in mammary epithelial and in breast cancer cells.
    Cancer Lett. 2017 Mar 10. pii: S0304-3835(17)30171.
    PubMed     Text format     Abstract available

  31. DESHMUKH SK, Srivastava SK, Zubair H, Bhardwaj A, et al
    Resistin potentiates chemoresistance and stemness of breast cancer cells: implications for racially disparate therapeutic outcomes.
    Cancer Lett. 2017 Mar 13. pii: S0304-3835(17)30174.
    PubMed     Text format     Abstract available


    Cancer Res

  32. SHIMELIS H, Mesman RL, Von Nicolai C, Ehlen A, et al
    BRCA2 hypomorphic missense variants confer moderate risks of breast cancer.
    Cancer Res. 2017 Mar 10. pii: canres.2568.2016.
    PubMed     Text format     Abstract available


    Clin Breast Cancer

  33. ALTUNDAG K
    Flap Fixation Using Tissue Glue or Sutures After Mastectomy Might Also Reduce Risk of Developing Lymphedema in Breast Cancer.
    Clin Breast Cancer. 2017 Feb 20. pii: S1526-8209(17)30061.
    PubMed     Text format    

  34. ALTUNDAG K
    Molecular Subtypes and Lower Inner Quadrant Tumors in Breast Cancer: Debate Is Still Ongoing.
    Clin Breast Cancer. 2017 Feb 17. pii: S1526-8209(17)30019.
    PubMed     Text format    


    Clin Cancer Res

  35. LEE H, Shields AF, Siegel BA, Miller KD, et al
    64Cu-MM-302 Positron Emission Tomography Quantifies Variability of Enhanced Permeability and Retention of Nanoparticles in Relation to Treatment Response in Patients with Metastatic Breast Cancer.
    Clin Cancer Res. 2017 Mar 15. pii: clincanres.3193.2016.
    PubMed     Text format     Abstract available

  36. SCHWARTZBERG LS, Yardley D, Elias A, Patel M, et al
    A Phase I/Ib Study of Enzalutamide Alone and in Combination with Endocrine Therapies in Women with Advanced Breast Cancer.
    Clin Cancer Res. 2017 Mar 9. pii: clincanres.2339.2016.
    PubMed     Text format     Abstract available


    Eur J Cancer

  37. VERMEULEN MA, Slaets L, Cardoso F, Giordano SH, et al
    Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program.
    Eur J Cancer. 2017 Mar 11. pii: S0959-8049(17)30726.
    PubMed     Text format     Abstract available

  38. GIACCHETTI S, Hamy AS, Delaloge S, Brain E, et al
    Long-term outcome of the REMAGUS 02 trial, a multicenter randomised phase II trial in locally advanced breast cancer patients treated with neoadjuvant chemotherapy with or without celecoxib or trastuzumab according to HER2 status.
    Eur J Cancer. 2017;75:323-332.
    PubMed     Text format     Abstract available


    Eur J Surg Oncol

  39. ALTUNDAG K
    Anti-HER2 neoadjuvant treatment may have an impact on discordance between preoperative core needle biopsy and surgical specimen in early breast cancer.
    Eur J Surg Oncol. 2017 Feb 21. pii: S0748-7983(17)30353.
    PubMed     Text format    


    Eur Radiol

  40. TIMMERMANS L, Bleyen L, Bacher K, Van Herck K, et al
    Screen-detected versus interval cancers: Effect of imaging modality and breast density in the Flemish Breast Cancer Screening Programme.
    Eur Radiol. 2017 Mar 13. doi: 10.1007/s00330-017-4757.
    PubMed     Text format     Abstract available


    Gene

  41. MANJEGOWDA MC, Gupta PS, Limaye AM
    Hyper-methylation of the upstream CpG island shore is a likely mechanism of GPER1 silencing in breast cancer cells.
    Gene. 2017 Mar 7. pii: S0378-1119(17)30141-5. doi: 10.1016/j.gene.2017.
    PubMed     Text format     Abstract available


    Int J Cancer

  42. BRINTON LA, Awuah B, Clegg-Lamptey JN, Wiafe-Addai B, et al
    Design considerations for identifying breast cancer risk factors in a population-based study in Africa.
    Int J Cancer. 2017 Mar 13. doi: 10.1002/ijc.30688.
    PubMed     Text format     Abstract available


    J Clin Oncol

  43. BARDIA A, Mayer IA, Diamond JR, Moroose RL, et al
    Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breast Cancer.
    J Clin Oncol. 2017 Mar 14:JCO2016708297. doi: 10.1200/JCO.2016.70.8297.
    PubMed     Text format     Abstract available


    J Nucl Med

  44. MORGAT C, MacGrogan G, Brouste V, Velasco V, et al
    Expression of Gastrin-Releasing Peptide Receptor (GRPR) in Breast Cancer and its Association with Pathological, Biological and Clinical Parameters: A Study of 1432 Primary Tumors.
    J Nucl Med. 2017 Mar 9. pii: jnumed.116.188011. doi: 10.2967/jnumed.116.188011.
    PubMed     Text format     Abstract available


    J Pathol

  45. MUTTER RW, Riaz N, Ng CK, Delsite R, et al
    Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.
    J Pathol. 2017 Mar 15. doi: 10.1002/path.4890.
    PubMed     Text format     Abstract available


    JAMA

  46. MUTH CC
    Chemotherapy and Hair Loss.
    JAMA. 2017;317:656.
    PubMed     Text format    


    Oncogene

  47. HERNANDEZ-PEREZ S, Cabrera E, Salido E, Lim M, et al
    DUB3 and USP7 de-ubiquitinating enzymes control replication inhibitor Geminin: molecular characterization and associations with breast cancer.
    Oncogene. 2017 Mar 13. doi: 10.1038/onc.2017.
    PubMed     Text format     Abstract available


    Oncol Rep

  48. JANG IS, Park JW, Jo EB, Cho CK, et al
    Growth inhibitory and apoptosis-inducing effects of allergen-free Rhus verniciflua Stokes extract on A549 human lung cancer cells.
    Oncol Rep. 2016;36:3037-3043.
    PubMed     Text format     Abstract available

  49. RATAJCZAK-WIELGOMAS K, Grzegrzolka J, Piotrowska A, Gomulkiewicz A, et al
    Periostin expression in cancer-associated fibroblasts of invasive ductal breast carcinoma.
    Oncol Rep. 2016;36:2745-2754.
    PubMed     Text format     Abstract available

  50. ARMANDO RG, Gomez DM, Gomez DE
    AZT exerts its antitumoral effect by telomeric and non-telomeric effects in a mammary adenocarcinoma model.
    Oncol Rep. 2016;36:2731-2736.
    PubMed     Text format     Abstract available

  51. IIZUKA A, Kondou R, Nonomura C, Ashizawa T, et al
    Unstable B7-H4 cell surface expression and T-cell redirection as a means of cancer therapy.
    Oncol Rep. 2016;36:2625-2632.
    PubMed     Text format     Abstract available


    PLoS Comput Biol

  52. NALDI A, Larive RM, Czerwinska U, Urbach S, et al
    Reconstruction and signal propagation analysis of the Syk signaling network in breast cancer cells.
    PLoS Comput Biol. 2017;13:e1005432.
    PubMed     Text format     Abstract available


    PLoS One

  53. AZAD AK, Lawen A, Keith JM
    Bayesian model of signal rewiring reveals mechanisms of gene dysregulation in acquired drug resistance in breast cancer.
    PLoS One. 2017;12:e0173331.
    PubMed     Text format     Abstract available

  54. LIU Y, Gu F, Liang J, Dai X, et al
    The efficacy and toxicity profile of metronomic chemotherapy for metastatic breast cancer: A meta-analysis.
    PLoS One. 2017;12:e0173693.
    PubMed     Text format     Abstract available

  55. NG CG, Mohamed S, Kaur K, Sulaiman AH, et al
    Perceived distress and its association with depression and anxiety in breast cancer patients.
    PLoS One. 2017;12:e0172975.
    PubMed     Text format     Abstract available

  56. KLEBANER D, Hamilton-Dutoit S, Ahern T, Crawford A, et al
    Apolipoprotein D expression does not predict breast cancer recurrence among tamoxifen-treated patients.
    PLoS One. 2017;12:e0171453.
    PubMed     Text format     Abstract available

  57. HE X, Ye F, Zhao B, Tang H, et al
    Risk factors for delay of adjuvant chemotherapy in non-metastatic breast cancer patients: A systematic review and meta-analysis involving 186982 patients.
    PLoS One. 2017;12:e0173862.
    PubMed     Text format     Abstract available

  58. HENG J, Guo X, Wu W, Wang Y, et al
    Integrated analysis of promoter mutation, methylation and expression of AKT1 gene in Chinese breast cancer patients.
    PLoS One. 2017;12:e0174022.
    PubMed     Text format     Abstract available

  59. TOSCANI AM, Sampayo RG, Barabas FM, Fuentes F, et al
    Distinct ErbB2 receptor populations differentially interact with beta1 integrin in breast cancer cell models.
    PLoS One. 2017;12:e0174230.
    PubMed     Text format     Abstract available

  60. ZAK M, Biskup M, Macek P, Krol H, et al
    Identifying predictive motor factors for falls in post-menopausal breast cancer survivors.
    PLoS One. 2017;12:e0173970.
    PubMed     Text format     Abstract available


  61. Correction: Yes1 signaling mediates the resistance to Trastuzumab/Lap atinib in breast cancer.
    PLoS One. 2017;12:e0174493.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Breast Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: